Objectives. aPL are frequently present in SLE. In a well characterized SLE cohort we aimed at investigating the prevalence of aPL and assessing their analytical performance and clinical association by testing criteria specificities including LA, aCL IgG and IgM, anti-b2-glycoprotein 1 (antib2GP1) IgG and IgM, as well as the non-criteria aPS-PT IgG and IgM and anti-b2GP1 domain 1 (aD1) IgG.
Introduction
SLE is a chronic inflammatory condition due to altered immunologic tolerance, biologically characterized by the presence of auto-antibodies directed against ubiquitous autoantigens [1, 2] . aPL are often present and part of the ACR classification criteria for SLE [3, 4] . aPL represent a heterogeneous family of antibodies directed against phospholipids and phospholipid-binding proteins [5, 6] . The presence of aPL in SLE has been associated with an increased risk of thrombosis, and poor pregnancy outcomes as in primary APS [79] . In addition, aPL are linked to more severe SLE features, including valve disease, pulmonary hypertension, livedo reticularis, thrombocytopaenia, haemolytic anaemia, acute/chronic renal vascular lesions and moderate/severe cognitive impairment, worse quality of life and higher risk of organ damage [10, 11] . The current biological criteria for APS classification rely on the identification of LA using coagulation assays and/or by detecting anti-b2-glycoprotein 1 (antib2GP1) and aCL IgG or IgM with solid phase assays [12] .
Several additional antigenic specificities for aPL antibodies have recently attracted great interest [13] . The b2GP1 protein is composed of five domains, and domain 1 (D1), which is a cryptic epitope when b2GP1does not bind to anionic phospholipids, is thought to be preferentially recognized by antibodies in individuals with APS [1416] . Interestingly, conflicting results have been reported on the association of anti-D1 (aD1) IgG and thrombotic events, with some reports indicating an increased risk of thrombosis in individuals with aD1 IgG [14] and others not confirming such an association, particularly in SLE [17] .
Furthermore, IgG or IgM directed against the aPS-PT have been variably associated with thrombotic events. However, in a systematic review of published evidence, Sciascia et al. [18] report that the presence of aPS-PT IgG or IgM increases the risk (odds ratio = 5.11; 95% CI: 4.2, 6.3) of arterial and/or venous thrombosis.
Thus, while aD1 and aPS-PT IgG and IgM are not currently among the criteria antibodies for APS, we felt it to be of interest to investigate whether the presence of these non-criteria antibodies, in association or not with criteria antibodies, could provide additional information on the clinical picture in SLE patients. In this study, taking advantage of the Swiss SLE cohort [19] , we aimed to investigate: the prevalence at entry into the cohort of criteria and non-criteria aPL antibodies, tested in a central laboratory; their persistence over time; whether their presence and titres were correlated; and which combination of autoantibodies was most strongly associated with thrombotic events.
Methods
Plasma samples were obtained from 178 individuals satisfying at least four ACR SLE criteria and consecutively enrolled in the prospective Swiss SLE Cohort Study (SSCS) from April 2007 to January 2015 [19] . A second, follow-up sample was obtained from 105 individuals of the original cohort for a total of 283 distinct samples. Median interval (interquartile range) between the first and second samples was of 13.1 (3.661.4) months. Ethical clearance was obtained in all participating SSCS centres. Informed, written consent was obtained from all participants according to the Declaration of Helsinki. All samples (N = 283) were tested in a single laboratory in Geneva (Hemostasis Unit, University Hospital, Switzerland). LA was detected using ACL TOP (Instrumentation Laboratory, Paris, France), which detected the ability to prolong two phospholipid-dependent tests: the silica clotting time (SCT) and the dilute Russell's viper venom time (dRVVT). The presence and titre of aCL and antib2GP1 IgG and IgM antibodies was assessed using the HemosIL AcuStar Coagulation Analyzer (Instrumentation Laboratory, Bedford, MA, USA) [20, 21] . The cut-off values for these tests were based on the 99th percentile and the corresponding 95% CI for each antibody of 626 healthy blood bank donors [21] . aPS-PT IgG and IgM antibodies were determined by ELISA using QUANTA Lite kits using the DSX automated apparatus (DSX/best 2000; INOVA, San Diego, CA, USA). aD1 antibodies were determined with the HemosIL AcuStar Coagulation Analyzer using QUANTA Flash. Reagent Kits were kindly provided kindly supplied by INOVA (Bettlach, Switzerland).
All tests were carried in duplicate [22] . aCL IgG and IgM cut-offs were 14 and 19 IU/ml, respectively; antib2GP1 IgG and IgM cut-offs were 17 and 12 IU/ml, respectively [21] ; for both aPS-PT IgG and IgM the cut-off was 30 IU/ml, according to manufacturer recommendations. The aD1 cut-off was 14.4 IU/l, based on the 99th percentile obtained by testing the plasma of 195 healthy women as previously reported [23] . When biological duplicate samples were assessed, infraclass correlation coefficients were >90% for all tests (supplementary Table S1 , available at Rheumatology online).
Thrombotic events
Venous and arterial thrombotic events were recorded at inclusion into SSCS and at subsequent visits. Consistent with the SLE Damage Index (SDI) [24] as used in the PROFILE study [25] , arterial vascular events were documented if myocardial infarction, angina pectoris and/or a vascular procedure for myocardial infarction (coronary artery bypass graft), cerebral vascular accident and claudication lasting 56 months and/or evidence of gangrene or significant tissue loss (loss of a digit or a limb) had occurred. Venous thrombotic events were deep venous thrombosis and or pulmonary embolism. Only the first incident event was taken into consideration. By definition, these events were recorded in SDI only if 6 months had elapsed since the diagnosis of SLE had been made.
Statistical analysis
We computed the proportions of patients who were positive for any of the nine aPL tests. We also defined categories of positivity as single, double or triple, according to the number of positive results for antibodies against cardiolipin (IgG or IgM), b2GP1 (IgG or IgM) and the LA (dRVVT or SCT). We examined the levels of non-criteria antibodies across categories of positivity. We obtained Pearson correlation coefficients between the nine test titres or results, which were logarithm-transformed to reduce the skewness of the distributions. To explore the pattern of associations between the tests, we conducted an exploratory factor analysis on the logarithm-transformed variables, followed by varimax rotation [26] . We examined the sampling adequacy of the exploratory factor analysis using the Kaiser-Meyer-Olkin statistic (desirable value >0.8), retained factors whose eigenvalue was >1, and obtained the proportion of total variance explained by the retained factors. To explore the clinical relevance of the retained factors, we examined their associations with the presence of vascular events (venous, arterial or both).
To examine the reliability of the laboratory procedures, we obtained intraclass correlation coefficients on the titres obtained for doubly processed samples; this was done for only a subset of the samples [27] .
To examine the stability of aPL over time, we computed kappa statistics (for results defined as positive or negative) and intraclass correlation coefficients (for continuous titres) for pairs of assessments obtained over time in the same patient, usually distant by several months.
All tests were two sided and assessed at the 5% significance level. Statistical analyses were performed using SPSS version 22 (IBM Corp, Armonk, NY).
Results

Characteristic of the study population
In this study, we included 178 individuals of whom 156 (87.6%) were women. The SLE clinical characteristics of the individuals included are summarized in Table 1 . The mean (S.D.) age at SLE diagnosis was 34.7 years (15.2) and 44.1 years (14.6) at inclusion in the cohort. Some 42.5% of the samples were positive for at least one classical aPL, 20.5% showed double and 12.6% triple positivity ( Table 2) . Of interest, six samples positive for aPS-PT IgG and 12 samples positive for aPS-PT IgM were negative for criteria aPL. Indeed, the frequency of single-positive aPS-PT IgM and aPS-PT IgG was higher than the frequency of single-positive samples for the other assessed specificities, being >7.4% for aPS-PT and <3.7% for the others. Concerning specifically LA and aPS-PT IgG, 19 samples were positive for both, 10 positive for aPS-PT IgG alone and 21 for LA alone. All but one aD1 IgG (15%) positive sera were also positive for antib2GP1 IgG. No statistically significant differences in the ACR criteria, disease activity as captured by (Safety of Estrogens in Lupus National Assessment, SELENA-SLEDAI) and Physician Global Assessment as well as damage as captured by SLICC-SDI were observed between positive and negative sera for criteria aPL (data not shown). In addition, no statistically significant differences were observed in the frequency of positive samples, for all nine aPL tests performed, whether or not the patients were under CS treatment or whether disease activity captured by SELENA-SLEDAI was 06 or >6 (data not shown).
Correlation between criteria and non-criteria aPL antibodies titres
We assessed whether there was a relationship in the titres of aPL tests obtained with the nine assays performed.
While they all were positively correlated (P < 0.001), the level of correlation was very high only for a few of them (Table 3) . Thus, the strongest correlations with a Pearson correlation coefficient (r) value of about 0.8 were observed for aD1 IgG with antib2GP1 IgG and aCL IgG (denoted with the superscript b in Table 3 ). Similarly, aCL IgM and antib2GP1 IgM was also strongly correlated. Lower levels of correlation (Pearson's r between 0.48 and 0.59) were found between dRVVT and IgG titres of aCL, antib2GP1, aD1, and aPS-PT IgG and IgM aPS-PT IgM (denoted with the superscript c in Table 3 ). The correlations were weakest between aPS-PT IgG/IgM, aCL IgG/IgM and antib2GP1 IgG, as well as aD1 IgG.
Given the substantial heterogeneity in aPL titres in SLE patients, we conducted an exploratory factor analysis to identify patterns of antibody responses. This analysis suggested three factors with an eigenvalue >1, which together explained 79.5% of total variance ( Table 4 ). The measure of sampling adequacy was 0.82, above the threshold of 0.8. Factor 1 grouped aCL IgG, antib2GP1 IgG and aD1 IgG. Factor 2 grouped dRVVT, SCT and aPS-PT IgG. Factor 3 grouped aCL IgM, antib2GP1 IgM and aPS-PT IgM. Thus, the nine tests performed provide results that can be grouped into three homogeneous ensembles. Interestingly, these groups respect isotypes differences and only aPS-PT IgG significantly aggregates with LA.
To further address the correlation and concomitant positivity between criteria and non-criteria antibodies we assessed the titre of aD1 IgG and aPS-PT IgG and IgM in samples with no, single, double or triple positivity according to criteria assays. As expected, the titre of the three non-criteria antibodies increased with the increase of the number of positive criteria assays. However, we observed an exquisite enrichment for high aD1 IgG titres in triplepositive samples, increasing by more than two orders of magnitude from no positive to triple-positive criteria sera (supplementary Table S2 , available at Rheumatology online). For comparison, in the same groups aPS-PT titres increased by 5-fold only for both IgG and IgM (supplementary Table S2 , available at Rheumatology online). Thus, in SLE sera there is a preferential enrichment for high titre aD1 IgG in triple-positive samples.
Persistence of aPL
The next question we asked was whether the presence or absence of individual aCL antibody specificities was sustained over time by assessing sera taken on average 1 year apart in 105 individuals. The clinical characteristics of these individuals did not significantly differ from the initial population (supplementary Table S3 , available at Rheumatology online). Overall, positivity or negativity was sustained over time (supplementary Table S4 , available at Rheumatology online). Kappa statistics revealed that SCT was the least persistent. In addition, aCL IgG as well as aPS-PT IgG and IgM had a kappa statistic ranging from 0.69 to 0.74, thus indicating some variation over time. However, the intraclass correlation coefficients on continuous measurements were very high for all tests (except for SCT), ranging from 0.83 to 0.99 (supplementary Table S4 , available at Rheumatology online), thus indicating that results located near the cut-off values could explain most of the variations observed for dichotomous results.
Association of aPL tests with thrombotic events
We next addressed the question of whether aPL was associated with thrombotic events in our SLE cohort. The overall frequency of thrombotic events was low. Twenty-two venous, 20 arterial and 37 either venous or arterial events were recorded. Among the nine distinct assays performed to detect aPL antibodies, only aPS-PT IgG titres were associated significantly with venous and composite venous or arterial events (supplementary Table S5 , available at Rheumatology online). To substantiate these findings, we used the presence or absence of aPS-PT antibodies as a dichotomous variable and assessed their association with thrombotic events. aPS-PT IgG but not aPS-PT IgM was strongly associated (P = 0.012) with venous thrombotic events and to a lesser extent to the composite arterial and venous vascular events (P = 0.077) ( Table 5 ). In addition, when using the three factors obtained by exploratory factor analysis only the factor that grouped LA and anti-PS-PT IgG was positively associated with thrombotic events, and the association was statistically significant for the composite of venous and arterial events ( Table 6 ). The factor grouping aCL IgG, antib2GP1 IgG and aD1 IgG had much weaker association, while the factor grouping aCL IgM, antib2GP1 IgM and aPS-PT IgM had a negative association with vascular events (factor scores were lower in patients with events); neither one of the latter was statistically significant. Of interest, when triple (data not shown) or quadruple (supplementary Table S6 , available at Rheumatology online) positive samples were taken into consideration, the association with vascular thrombotic events was statistically significant only for IgG responses. Thus, the non-criteria aPS-PT IgG-by itself and in conjunction with LA-appears to be associated with thrombotic events in Swiss SLE patients.
Discussion
Taking advantage of the Swiss SLE cohort [19] as well as of the availability of novel commercial kits to assess the presence of aPS-PT IgG and IgM as well as aD1 IgG, our study examined the analytical performance of nine tests aiming at detecting aPL antibodies and their clinical associations. Our results show that: the tests employed here provide reliable results; aPL tend to persist with time; the titres of criteria and non-criteria aPL all correlate, but vary considerably in the strength of correlations; exploratory factor analysis identifies three groups of specificities segregating aPL isotypes and grouping LA only with aPS-PT IgG; high titre aD1 IgG are highly enriched in triple-positive samples; and aPS-PT IgG-by itself and in combination with LA-stands out in patients with an history of thrombotic events. The reproducibility of results is, of course, essential to provide reliable conclusions. While all samples were tested with technical duplicates, we tested also biological duplicates in a random subgroup of about 70 patients (supplementary Table S1 , available at Rheumatology online). The results obtained were robust and satisfied the requirements of consensus experts [12] . This allowed the study of the persistence of aPL in time. As expected, and in agreement with published data [28] , most negative samples remained negative 1 year apart, while somehow, less frequently positive samples remained positive. Low titre antibody positivity explained most of this variability, which was independent of treatment (data not shown). Most importantly, techniques of dosage and cut-off values used here were validated in previous studies by us and similar to those used by others [20, 21, 23, 2932] .
The investigation of concordance and discordance among the aPL assays provided interesting data that complement previous studies. Overall, the correlation coefficients between the tests expressed as continuous variables were statistically highly significant, which is in line with previous reports by us and others [14, 17, 20, 23, 32, 33] . However, the correlation coefficients varied substantially among pairs of tests. The exploratory factor analysis identified the underlying three factors that associated the tests in three distinct groups: one grouping aCL IgG, antib2GP1 IgG and aD1 IgG, a second grouping LA and aPS-PT IgG and the third grouping aCL IgM, antib2GP1 IgM and aPS-PT IgM. The association of specificities we found in the first group has already been documented in the literature [20, 32, 33] , and indeed D1 has been previously shown to be the immune-dominant epitope of b2GP1 IgG. Previous studies, however, focused on the performance of the tests in an APS patient population with a high prevalence of thrombotic events [34] , which is not the case in our SLE cohort. Our factor three grouped IgM responses, with very high correlation coefficients, much higher than those correlating IgM with IgG specific for the same antigen. This indicates that some SLE patients are developing IgM responses against distinct phospholipid (PL) specificities that are sustained in time and do not tend to switch to IgG. Of interest, IgM specificities had similar correlation coefficients with dRVVT to those of their IgG counterpart. In this perspective, our results are in agreement with previous data indicating association of aCL IgM, antib2GP1 IgM and aPS-PT IgM with LA [17] and support the contention that IgM may also contribute to LA. Finally, our factor two grouped LA (both dRVTT and/or SCT) and aPS-PT IgG. Thus, aPS-PT IgG in our study appears to have distinct characteristics compared with the other IgG aPL assays. This, may be reflected in biological properties which may then have clinical impact as discussed here below.
Several studies have reported that patients with triplepositive aPL carry a particularly high risk of thrombotic events [8, 32, 3537] . Furthermore, aD1 IgG was shown to be elevated in triple-positive sera [38, 39] . Our study confirms that aD1 IgG are particularly high, in triple-positive sera, possibly more than aPS-PT IgG (and aPS-PT IgM) in SLE patients. In contrast, we did not confirm the previous observation that among antib2GP1-positive patients aD1 positivity implies an increased risk of thrombotic events [14] . This is consistent with other reports in SLE [17] . Two non-mutually exclusive hypotheses may explain this discrepancy. First, the epitopes within aD1 recognized by SLE IgG may differ from those recognized by primary APS. This may affect their pro-thrombotic activity. Second, thrombotic events in SLE may be due, at least in part, to factors independent form aPL, which contribution may lessen the importance of aD1 IgG.
In our cohort, the presence of aPS-PT IgG was particularly associated with venous thrombotic events, and interestingly the combination of aPS-PT IgG with LA-identified in the exploratory factor analysis-was associated in a statistically significant manner when venous and arterial events were grouped. This confirms data by others in primary APS [18] and in SLE [17] . However, many other studies identified also aCL IgG/IgM and antib2GP1 IgG/IgM to be associated with thrombosis [4042] . These differences may be due to the clinical characteristic of the SLE patients enrolled in our cohort and in particular to the relatively low incidence of thrombotic events (21%) when compared with other study populations where the prevalence of such events ranged from 25 to 50% [17, 42, 43] , thus reducing the power of the statistical analysis we conducted. This may further explain why in our cohort aD1 IgG was not associated with thrombotic events in contrasts with the findings of others in APS [37] .
A further point of interest is that, due to their strong association with LA and with vascular events, the assessment of of aPS-PT IgG in substitution of LA may particularly useful in anticoagulated patients in which the determination of LA is technically difficult.
It has to be stressed that our study population was followed in tertiary centres across Switzerland, patients attended by internal medicine, nephrology, clinical immunology and rheumatology specialists. This may represent a blend of patients that may differ from those attended to in dedicated, single centres. A weakness of our study is that ours is not an inception cohort, and most thrombotic events were recorded by review of the clinical charts. Others have found that thrombotic events accumulate with time, particularly in triple-positive individuals [35] . It is possible that the prospective follow-up of our cohort will reveal other associations. As an additional limitation, we did not include in our study aPL IgA or other non-criteria PL specificities beside PS-PT and D1, thus limiting the potential for detecting important clinical associations. However, the analytical performance of our study met the highest standards and results were highly reproducible. Exploratory factor analysis performed according to Bartko [27] . Three factors with an eigenvalue >1, explaining 79.5% of total variance, are reported. Mean values of three factors combining aPL in the presence and absence of thrombotic events, in 162 patients (16 had missing data). All factors had a mean of 0 and S.D. of 1 in the whole sample. The measure of sampling adequacy was 0.82, above the threshold of 0.8. Antib2GP1: anti-b2-glycoprotein 1; aD1: anti-domain 1 of b2GP1.
In conclusion, our study stresses the importance of aPS-PT IgG in identifying patients at risk for thrombosis in SLE and suggests the usefulness of adding this specificity when searching for aPL antibodies. Prospective studies are needed to support this contention.
